| 产品详情 |
| Edit |   |
|---|
| Product Name | Von Hippel-Lindau Protein, Recombinant, Human (vHL) |
|---|
| Description | Purity ≥ 95% as determined by RP-HPLC, anion-exchange FPLC and/or reducing and non-reducing SDS-PAGE Silver Stained gel. Von Hippel-Lindau disease(VHL) is a dominant inherited syndrome characterized by the predisposition to develop various kinds of benign and malignant tumors, including clear cell renal carcinomas, pheochromocytomas and hemangioblastomas of the central nervous system and retina. VHL syndrome is caused by germline mutation in the VHL tumor suppressor, and VHL tumors are associated with loss or mutation of the remaining wild-type allele. VHL has two domains: a roughly 100-residue NH2-terminal domain rich in beta sheet(beta-domain) and a smaller alpha-helical domain (alpha-domain), held together by two linkers and a polar interface. VHL protein is also involved in the degradation of hypoxia-inducible factor (HIF). Description: Recombinant Human VHL beta-domian is a single,non-glycosylated polypeptide chain containing 174aa and has a molecular mass of 19.2kD. Sequence: MGS |
|---|
| Size | 10ug, 50ug |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | n/a |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | V2640-14 |
|---|
| Price | |
|---|
| Order / More Info | Von Hippel-Lindau Protein, Recombinant, Human (vHL) from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|